gabapentin + oxybutynin

DDP-200 is an oral, fixed-dose combination of gabapentin and oxybutynin developed by Dynogen for the treatment of non-incontinent forms of overactive bladder (OAB), with a particular focus on patients experiencing urinary frequency, urgency, and nocturia. The combination targets both afferent and efferent neurological pathways serving the bladder, potentially benefiting both sensory and motor aspects of OAB. Preclinical models demonstrated statistically significant synergy between gabapentin and oxybutynin at low doses, suggesting improved efficacy over oxybutynin alone while reducing side effects associated with higher doses. This investigational therapy aims to enhance efficacy and tolerability compared to existing OAB treatments[1].

Other names

DDP200DDP-200DDP 200